Song, Y., et al. Tumor Microenvironment Associated with complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action. Blood Journal 2020. NOV 5 136(S1):10-11.
Davies, A., et al. Acalbrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase lb/ll Single Arm Study. Blood Journal 2020 NOV 5 136 (S1):88-89.
Gaudio, E., et al. Analysis of Adct-602 Pre-Clinical Activity in B-Cell Lymphoma Models and Identificaton of Potential Biomarkers for Its Activity. Blood Journal 2020 NOV 6. 136 (S1);17
Tiemann, A., et al. Comparison of immunohistochemical and gene expression profiling based subtype identification of diffuse large B-cell lymphoma. Focus on extranodal lymphoma. Poster and Abstract 263 presentedDeutsche Gesellschaft Fur Hamatologie Und Medizinische Onkologie. at Virtual Annual Meeting 2020 OCT 9 - 11.
Tarantelli, C., et al. The Antibody-Drug Conjugate (ADC) Loncastuximab Tesirine (ADCT-402) Targeting CD19 Shows Strong Invitro Anti-Lymphoma activity Both as Single Agents and in Combination. Paper presented at: 15th International Conference on Malignant Lymphoma Palazzo dei Congressi; 2019 Jun 18-22; Lugano, Switzerland. Hematological Oncology VOL 37, Issue S2. https://doi.org/10.1002/hon.90_2629
Balasubramanian, S., et al. Concordance Between Immunohistochemistry and Gene Expression Profiling Subtyping for Diffuse Large B-Cell Lymphoma in the Phase 3 Phoenix Trial. Hematological Oncology. 2020(37)S2.
Richter, J. et al, Cell-of-origin classification of diffuse large B-cell lymphoma - comparison of molecular tests and extension to the PETAL trial. Abstract presented at: 102nd Annual Meeting of the German Society for Pathology 2018 May 24 – 16; Berlin, Germany Abstract, #AG02.16
Bertoni, F., et al. PQ309 is a novel dual P13K/mTOR inhibitor with pre-clinical anti-tumor activity in lymphomas as a single agent and in combination therapy. Clin Cancer Res. Clin Cancer Res. 2018 Jan 1;24(1):120-129. doi: 10.1158/1078-0432.CCR-17-1041. Epub 2017 Oct 24. [Epub ahead of print].
Reinholz M., et al. Gene Expression Measurement of Immuno-Oncology Targets in a Single FFPE Section Using a Novel Targeted Sequencing Assay. Cancer Res. July 15 2016;76(14 Suppl):abstr 2237.
Page last updated May 22, 2023